Investing in the future of healthcare
17.5VC is a specialist fund-of-funds investing in the next generation of healthcare innovation – Healthcare 5.0. We connect accredited investors to exceptional, difficult-to-access venture capital funds driving breakthroughs in diagnostics, digital health, biotech, and med-tech, deliver diversified exposure, professional diligence, and institutional-grade strategy at a private scale.
What We Deliver to Investors
Exclusive Access
17.5VC opens doors to top-tier healthcare venture capital funds usually closed to individual investors, providing entry to high-potential deals.
Diversified Exposure
Our FoF offers access to hundreds of startups across sectors, stages, and regions – reducing risk and improving return potential.
Institutional-Grade Management
Investors benefit from professional portfolio management and due diligence without requiring large capital commitments.
Co-Investment Opportunities
17.5VC offers the chance to co-invest alongside leading VCs in select high-growth companies, amplifying potential returns.
Partnering With Top VC Managers
17.5VC’s curated portfolio aims for resilience and outperformance by balancing four critical dimensions of venture capital allocation.
Sector Focused
We invest across healthcare sectors—health-tech, biotech, med-tech, diagnostics and digital therapeutics—to capture both near-term adoption and long-term breakthroughs.
Global Reach
Our geographic spread spans top global innovation hubs, ensuring exposure to diverse regulatory and market dynamics.
Multistaged
We emphasize early and mid-stage funds while maintaining targeted seed and growth exposure to optimize returns and manage risk.
specialized gPs
We focus on small-to-mid-sized specialist funds that outperform larger peers, offering stronger founder alignment, better deal access, and exposure to top-tier venture opportunities.
Team
DAVID NICHTENHAUSER
A Founding Partner at 17.5VC and a seasoned investment professional with over 25 years of experience in portfolio management, asset allocation, and investment due diligence. Most recently, he led a multi-national integration program at a Singapore-based medical information and diagnostics company, where he played a key role in a private equity roll-up. Prior to that, David co-founded two companies focused on augmented analytics, combining his deep investment background with big data technologies to support decision-making in complex systems.
Earlier in his career, David held senior investment roles at ABN Amro, LGT Capital Partners, and the Abu Dhabi Investment Authority (ADIA). At ADIA, he served as Portfolio Manager and Executive Committee Member, where he was directly responsible for a $5 billion portfolio of alternative investments. His tenure across these global institutions was marked by rigorous manager selection, investment due diligence, and portfolio construction for institutional clients and fund-of-funds platforms. David’s extensive global investment experience and operational leadership uniquely position him to identify and evaluate specialist venture capital managers advancing the future of healthcare technology. He hold a bachelor of science degree in applied economics from Cornell University.
Dr. Shaun Kuan
Dr. Shaun Kuan is a physician-turned-venture investor with over a decade of experience spanning clinical practice, product leadership, and healthtech entrepreneurship across Asia. Most recently, he served as Chief Product Officer at a private equity-backed diagnostics and digital health company operating in nine countries, where he led product strategy and delivery across clinical, lab, and enterprise systems at national scale. Shaun also played a pivotal role in the company’s private equity roll-up strategy. Prior to that, he was a founding executive at NADI Health and co-founder of Savor of Life, where he helped launch and scale digital therapeutics and health SaaS platforms for both consumers and institutions. Across these ventures, Shaun has consistently led multi-functional teams at the intersection of healthcare delivery, software innovation, and commercialization.
Shaun is a Founding Partner at 17.5VC, where he brings a unique perspective as a clinician, operator, and investor to identifying specialist venture capital firms focused on transformative health and medical technologies. His active roles as investor and strategic advisor to healthtech startups and venture studios—including VentureBlick and QmedAsia—reflect his deep network and insight into early-stage innovation. A certified lifestyle medicine physician and graduate of Harvard Medical School’s Metabolic Health program, Shaun blends clinical rigor with entrepreneurial execution
Dr. Anthony Lawrence
Anthony is a physician-turned-operator and investor with deep experience across healthcare systems, digital platforms, and venture capital. He has held leadership roles in both multi-billion-dollar corporations and high-growth startups, combining clinical insight with commercial and strategic investment expertise.
At GE HealthCare, he led marketing, strategy, and operations across ASEAN, Korea, and ANZ—a $1B region—achieving 13% annual growth. He also served as CEO of GE Healthcare Indonesia, reinforcing its market leadership. Prior to GE, Anthony was CEO of BioMark, a TPG-backed company, where he scaled the platform to over 8,000 practices and one million patients across Southeast Asia.
Earlier, he was a venture partner at a Southeast Asia VC firm, delivering MOICs of 10–30x and IRRs as high as 400% across tech startups. He holds degrees in Medicine and Biomedical Sciences from University College Dublin, a Master’s in Internal Medicine from the University of Edinburgh, and an MBA from Chicago Booth.